NEW YORK (GenomeWeb) – Targos will provide its expertise, biomarker services, and quality standards to support WuXi PharmaTech's bioanalytical work for pharmaceutical customers as part of a biomarker collaboration announced today by the companies.

Targos and WuXi will focus on validating and analyzing clinical tissue biomarkers in cancer, they said, adding Targos is providing training and education to help pathologists and histotechnologists produce accurate, objective, and reproducible diagnostic results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.